

# Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

## WuXi AppTec Laboratory Services

RRID:SCR\_001217

Type: Tool

---

### Proper Citation

WuXi AppTec Laboratory Services (RRID:SCR\_001217)

---

### Resource Information

**URL:** <http://www.wuxiapptec.com>

**Proper Citation:** WuXi AppTec Laboratory Services (RRID:SCR\_001217)

**Description:** A commercial organization for pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations.

**Resource Type:** material resource, instrument supplier

**Keywords:** commercial, pharmaceutical, biopharmaceutical, medical device, open access, open access capability, open access technology platform

**Availability:** Commercial

**Resource Name:** WuXi AppTec Laboratory Services

**Resource ID:** SCR\_001217

**Alternate IDs:** nlx\_30524

**License URLs:** <http://www.wuxiapptec.com/term.html>

**Record Creation Time:** 20220129T080206+0000

**Record Last Update:** 20260808T190545+0000

---

### Ratings and Alerts

No rating or validation information has been found for WuXi AppTec Laboratory Services.

No alerts have been found for WuXi AppTec Laboratory Services.

---

### Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Dummer R, et al. (2025) Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(11), 2097.

Rastogi S, et al. (2025) Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation. Cancer research communications, 5(4), 668.

Giardiello M, et al. (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature communications, 7, 13184.